phase readout
saveNCT06671938: Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy
ACTIVE_NOT_RECRUITINGupdated 1mo ago
community read0 votes
Sponsor: BioArctic AB. Phase: PHASE2. Conditions: Parkinson Disease, Multiple System Atrophy
view source ↗
comments(0)
5-min edit window · permanent after that